Prevalence of and risk factors for low bone mineral density in Spanish treated HIV-infected patients

Low Bone Mineral Density in Vertically HIV-infected Children and Adolescents

(2017) Beatriz Jiménez et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals

(2016) Philip M. Grant et al.   JOURNAL OF INFECTIOUS DISEASES

Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) A Carr et al.   HIV MEDICINE

Relative contribution of HIV infection, demographics and body mass index to bone mineral density

(2014) Aoife G. Cotter et al.   AIDS

Low Bone Mineral Density in Patients With Well-Suppressed HIV Infection: Association With Body Weight, Smoking, and Prior Advanced HIV Disease

(2014) Katherine W. Kooij et al.   JOURNAL OF INFECTIOUS DISEASES

Incident fractures in HIV-infected individuals

(2013) Stephanie Shiau et al.   AIDS

The relationship between serum 25-hydroxy vitamin D, parathormone and bone mineral density in Indian population

(2013) M. K. Garg et al.   CLINICAL ENDOCRINOLOGY

Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients

(2013) J. L. Casado et al.   OSTEOPOROSIS INTERNATIONAL

Prevalence of Vitamin D Deficiency and Its Related Risk Factor in a Spanish Cohort of Adult HIV-Infected Patients: Effects of Antiretroviral Therapy

(2012) Miguel Cervero et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Low Bone Mass in Behaviorally HIV-Infected Young Men on Antiretroviral Therapy: Adolescent Trials Network Study 021B

(2012) K. Mulligan et al.   CLINICAL INFECTIOUS DISEASES

Body composition changes after switching from protease inhibitors to raltegravir

(2011) Adrian Curran et al.   AIDS

Incidence of low and high-energy fractures in persons with and without HIV infection

(2011) Ann-Brit E. Hansen et al.   AIDS

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

(2011) Grace A. McComsey et al.   JOURNAL OF INFECTIOUS DISEASES

High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study

(2010) Anna Bonjoch et al.   AIDS

HIV and bone disease

(2010) Benjamin Stone et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study

(2010) Hans‐Jürgen Stellbrink et al.   CLINICAL INFECTIOUS DISEASES

Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial*

(2010) AB Hansen et al.   HIV MEDICINE

Reduced bone mineral density in HIV-infected patients: prevalence and associated factors

(2009) Charles Cazanave et al.   AIDS

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients

(2009) Claudine Duvivier et al.   AIDS

Simplification of Antiretroviral Therapy with Tenofovir‐Emtricitabine or Abacavir‐Lamivudine: A Randomized, 96‐Week Trial

(2009) Allison Martin et al.   CLINICAL INFECTIOUS DISEASES

A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression

(2009) Esteban Martínez et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES